Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $60.61M
• Dividend Yield: N/A
• Average Volume (3M): 142.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: -55.47%
• EPS Growth: 24.92%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 77,708,534
• 10 Day Avg. Volume: 185,418
• 30 Day Avg. Volume: 142,197
• PEG Ratio: -0.17
• Price to Book (P/B): -1.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.88
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 3.00
• Enterprise Value/Gross Profit: 42.73
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $5.40
• Price Target Upside: 610.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 44 Neutral
• Price Target: $1.00 ▲(31.58%Upside)

Clearside Biomedical's overall stock score is primarily impacted by its weak financial performance and valuation concerns. While there are positive developments in clinical trials and partnerships, the financial instability and requirement for additional funding weigh heavily on the score. Technical analysis also suggests a lack of strong momentum, contributing to the low score.

Positive Factors

Analyst Rating

Analyst reiterates Buy rating while adjusting the 12-month price target to $5.

Regulatory Approval

Arctic Vision's New Drug Application for ARCATUS was accepted for review in China and approved in Australia and Singapore for the treatment of uveitic macular edema.

Negative Factors

Financial Needs

The company needs to raise capital to fund the Phase 3 program.

Financial Performance

Net loss totaled $8.2M in search of funding for Phase 3 wet AMD program.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Clearside Biomedical makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue through licensing agreements, partnerships, and collaborations with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and sharing of development costs. Additionally, Clearside may earn income from the sale of its proprietary drug candidates once they receive regulatory approval. The company's revenue streams are closely tied to the successful advancement of its pipeline and strategic alliances that facilitate broader market access for its therapies.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical's financials demonstrate significant challenges, with declining revenues, consistent losses, and a strained balance sheet. The company's reliance on external financing, negative equity, and inability to generate positive cash flows present substantial financial risks.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.43M	1.66M	8.23M	1.33M	29.57M	7.89M
	Gross Profit
1.28M	1.51M	7.87M	1.12M	29.40M	7.89M
	EBIT
-25.88M	-28.88M	-24.84M	-30.28M	-627.00K	-17.93M
	EBITDA
-20.22M	-24.35M	-23.06M	-29.46M	-449.00K	-17.93M
	Net Income Common Stockholders
-30.81M	-34.35M	-32.48M	-34.07M	376.00K	-18.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.63M	20.02M	28.92M	48.26M	30.44M	17.29M
	Total Assets
19.67M	25.13M	34.02M	51.30M	42.90M	19.32M
	Total Debt
619.00K	703.00K	43.00M	1.28M	675.00K	1.98M
	Net Debt
-13.01M	-19.32M	14.08M	-46.97M	-29.76M	-15.31M
	Total Liabilities
65.58M	63.98M	49.93M	40.70M	4.93M	10.56M
	Stockholders Equity
-45.91M	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow		Free Cash Flow
-23.60M	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
	Operating Cash Flow
-22.68M	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
	Investing Cash Flow
-590.00K	-638.00K	-1.78M	-246.00K	0.00	-55.00K
	Financing Cash Flow
1.54M	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.87, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 9.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.20B	3.32	-45.04%	2.84%	16.81%	-0.31%
ADAG	46 Neutral	$92.10M	―	-55.14%	―	-99.43%	-69.40%
CLSD	44 Neutral	$60.61M	―	91.63%	―	-55.47%	24.92%
IVVD	44 Neutral	$101.70M	―	-122.69%	―	―	20.91%
ADVM	41 Neutral	$47.21M	―	-127.99%	―	―	37.54%
INZY	37 Underperform	$255.02M	―	-141.69%	―	―	-17.06%
JSPR	35 Underperform	$85.33M	―	-101.34%	―	―	21.40%

Clearside Biomedical Corporate Events

Clearside Biomedical Approves Share Increase at Annual Meeting

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Reports 2024 Financial Results and Updates

On March 27, 2025, Clearside Biomedical announced its financial results for the fourth quarter and full year 2024, alongside a corporate update. The company reported a decrease in license and other revenue, attributing it to prior year milestone payments, and a net loss increase due to reduced revenue. Clearside highlighted its successful End-of-Phase 2 meeting with the FDA for CLS-AX in wet AMD, and its Asia-Pacific partner’s regulatory progress for ARCATUS® in China. The company also noted multiple collaborations and advancements in its suprachoroidal delivery platform, including Phase 3 plans for diabetic retinopathy and ocular oncology trials, positioning itself for potential pipeline expansion and strategic partnerships.